We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Mutation Causes Devastating Mitochondrial Diseases

By LabMedica International staff writers
Posted on 19 Sep 2013
A novel disease gene has been identified in which mutations cause rare but devastating genetic diseases known as mitochondrial disorder.

Mitochondrial diseases are caused by mutations in either mitochondrial DNA or in genes in the nucleus that encode for proteins that function in the mitochondria. More...


Scientists at the Loyola University Stritch School of Medicine (Maywood, IL, USA) and their multi-institute collaborators performed a battery of genetic tests to identify a nuclear gene that encodes for a protein called F-Box and Leucine-Rich Repeat Protein 4 (FBXL4).

They found that mutations of this FBXL4 gene lead to either truncated or altered forms of the protein. This results in cells having less mitochondrial DNA, decreased mitochondrial membrane potential and a faulty process in cell metabolism called oxidative phosphorylation. The study also proved that the FBXL4 protein is located exclusively in mitochondria, which was previously unrecognized.

The team used high-performance computer cluster to analyze billions of DNA sequences to identify the gene mutation in a child and her parents. The scientists then reached out to other collaborators to see if any of their patients also had the FBXL4 mutation. Eight additional affected children in six unrelated families were found to also have disease-causing mutations in this gene.

Biochemical assays performed on clinical basis in muscle and/or fibroblasts obtained from several subjects confirmed the deleterious effect of FBXL4 mutations on mitochondrial bioenergetics. Muscle homogenates or isolated mitochondria from subjects with FBXL4 mutations showed variably decreased activity of mitochondrial respiratory chain complexes.

The authors concluded that they provided evidence that recessive FBXL4 mutations are responsible for severe, infantile-onset mitochondrial encephalomyopathy. A child can inherit a mitochondrial disease either from the mother alone or from both parents carrying mutations in the same nuclear gene. Mitochondrial diseases affect between 1 in 4,000 and 1 in 5,000 people. The study was published on August 29, 2013, in the American Journal of Human Genetics.

Related Links:
Loyola University Stritch School of Medicine


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.